CHP134 has been reported to express the antiapoptotic BCL2 gene at extremely low levels, and to be used as a NB cell death model, i.e., cells would rather undergo apoptosis than neuronal differentiation in response to a treatment [23, 24]. This evidence concerns the gene BCL2 and neuroblastoma.